A human antibody with blocking activity to RBD proteins of multiple SARS-CoV-2 variants including B.1.351 showed potent prophylactic and therapeutic efficacy against SARS-CoV-2 in rhesus macaques
Deng, S.-J.; cao, X.; Gu, C.; Wang, Z.; Liu, P.; Liu, X.; Gao, L.; Jia, F.; Yu, L.; Li, N.; Jiang, G.; Zhang, J.; Yang, L.; Shi, M.; Hou, T.; Li, Y.; Liang, W.; Lu, G.; Yang, C.; Wang, Y.; Xia, K.; Xiao, Z.; Xue, J.; Huang, X.; Chen, X.; Pan, Z.; Wang, X.; Guo, H.; Liang, H.; Yao, Y.; Gao, G.; Peng, Y.; Hu, X.; Min, J.; Zhou, Y.; Liu, K.; Guo, W.; Yuan, Z.; Song, D.; Guan, W.; Ma, H.; Hu, X.; Zhang, Y.; Chen, Z.; Shan, C.
Show abstract
Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), which causes coronavirus disease-2019 (COVID-19), interacts with the host cell receptor angiotensin-converting enzyme 2 (hACE2) via its spike 1 protein for infection. After the virus sequence was published, we identified two potent antibodies against SARS-CoV-2 RBD from antibody libraries using a phage-to-yeast (PtY) display platform in only 10 days. Our lead antibody JMB2002, now in a phase I clinical trial, showed broad-spectrum in vitro blocking activity against hACE2 binding to the RBD of multiple SARS-CoV-2 variants including B.1.351 that was reportedly much more resistant to neutralization by convalescent plasma, vaccine sera and some clinical stage neutralizing antibodies. Furthermore, JMB2002 has demonstrated complete prophylactic and potent therapeutic efficacy in a rhesus macaque disease model. Prophylactic and therapeutic countermeasure intervention of SARS-CoV-2 using JMB2002 would likely slow down the transmission of currently emerged SARS-CoV-2 variants and result in more efficient control of the COVID-19 pandemic.
Matching journals
The top 10 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- Immunoglobulin fragment F(ab')2 against RBD potently neutralizes SARS-CoV-2 in vitro 95%
- A Novel High-Throughput Single B-Cell Cloning Platform for Isolation and Characterization of High-Affinity and potent SARS-CoV-2 Neutralizing Antibodies 94%
- DMBT1 promotes SARS-CoV-2 infection and its SRCR-derived peptide inhibits SARS-CoV-2 infection 94%
Similar papers in this journal
Similar papers in this journal
- Ultrapotent and Broad Neutralization of SARS-CoV-2 Variants by Modular, Tetravalent, Bi-paratopic Antibodies 97%
- A potent bispecific nanobody protects hACE2 mice against SARS-CoV-2 infection via intranasal administration 96%
- Human IgG neutralizing monoclonal antibodies block SARS-CoV-2 infection 95%
Similar papers in this journal
- A Bispecific Antibody Targeting RBD and S2 Potently Neutralizes SARS-CoV-2 Omicron and Other Variants of Concern 98%
- Potent in vitro Neutralization of SARS-CoV-2 by Hetero-bivalent Alpaca Nanobodies Targeting the Spike Receptor-Binding Domain 97%
- Glycan-reactive antibodies isolated from human HIV-1 vaccine trial participants show broad pathogen cross-reactivity 95%
Similar papers in this journal
- An ACE2 decamer viral trap as a durable intervention solution for current and future SARS-CoV 97%
- Impaired potency of neutralizing antibodies against cell-cell fusion mediated by SARS-CoV-2 95%
- One dose of COVID-19 nanoparticle vaccine REVC-128 provides protection against SARS-CoV-2 challenge at two weeks post immunization 94%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.